跳转至内容
Merck
CN

N0550000

新斯的明

European Pharmacopoeia (EP) Reference Standard

别名:

N,N,N-三甲基-2-[(二甲氨基)甲酰氧基]苯铵甲磺酸盐

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C13H22N2O6S
CAS号:
分子量:
334.39
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

neostigmine

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

格式

neat

SMILES字符串

COS([O-])(=O)=O.CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C

InChI

1S/C12H19N2O2.CH4O4S/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5;1-5-6(2,3)4/h6-9H,1-5H3;1H3,(H,2,3,4)/q+1;/p-1

InChI key

OSZNNLWOYWAHSS-UHFFFAOYSA-M

基因信息

human ... ACHE(43)

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Neostigmine methyl sulfate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

类似于毒扁豆碱的乙酰胆碱酯酶的可逆抑制剂,但是不能穿过血脑屏障。

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Skull and crossbonesHealth hazard

警示用语:

Danger

危险分类

Acute Tox. 2 Oral - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Michael Benatar et al.
The Cochrane database of systematic reviews, 12, CD005081-CD005081 (2012-12-14)
Approximately 50% of people with myasthenia gravis present with purely ocular symptoms, so called ocular myasthenia. Of these between 50% to 60% develop generalized disease, most within two years. Their management is controversial. This is an update of a review
Comparing sugammadex and neostigmine reversal of neuromuscular blockade in laparoscopic surgery.
D Jain et al.
Anaesthesia, 68(3), 306-307 (2013-02-07)
G V Cammu et al.
Anaesthesia and intensive care, 40(6), 999-1006 (2012-12-01)
Six years ago, a study performed in our department reported that the incidence of postoperative residual curarisation (PORC) was 39%. The reassessment of neuromuscular monitoring and reversal of neuromuscular block in routine anaesthetic practice is relevant now that sugammadex has
M O Akinwale et al.
African journal of medicine and medical sciences, 41(2), 231-237 (2012-11-29)
The spinal route of analgesia has consolidated its place as a major modality in the management of both acute and chronic pain. The search for ideal additives to local anaesthetic agents to prolong the analgesic effects poses a challenge to
Tetsufumi Sato et al.
Masui. The Japanese journal of anesthesiology, 62(1), 19-26 (2013-02-26)
Anticholinesterase, such as neostigmine, was used to be a standard drug at the end of surgery for reversal of nondepolarizing neuromuscular block. Neostigmine decreases the metabolism of acetylcholine (ACh) at the neuromuscular junction and allows its concentration to increase and

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门